



Total number of voting rights and shares

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 222-16 of the Règlement Général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority).

Date :	Total number of shares issued at a nominal price of € 0.15	Number of existing voting rights
As of March 18, 2013	19,667,481	26,969,607

About Neovacs

Neovacs is a biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that run until at least 2026) Neovacs is focusing its development efforts on two active immunotherapies: TNF-Kinoid is being developed for the treatment of TNF-mediated autoimmune diseases such as rheumatoid arthritis and Crohn's disease, whereas IFN α -Kinoid is being developed for the indication of lupus. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, visit www.neovacs.fr

Contacts

Press – ALIZE RP

Caroline Carmagnol
+33 (0)1 42 68 86 43
caroline@alizerp.com

NEOVACS

Nathalie Trépo
+33 (0)1 53 10 93 00
ntrepo@neovacs.com

Investors - NewCap

Valentine Brouchet
+ 33 (0) 1 44 71 94 93
vbrouchet@newcap.fr